UroGen Pharma (URGN) Interest & Investment Income (2019 - 2026)
UroGen Pharma (URGN) posted Interest & Investment Income of $608000.0 for Q1 2026, down 88.59% on a QoQ basis from $5.3 million in Q4 2025, and down 71.24% year-over-year from $2.1 million in Q1 2025.
UroGen Pharma (URGN) Interest & Investment Income (2019 - 2026) Analysis & Trends
UroGen Pharma's Interest & Investment Income history runs 8 years deep, the most recent figure standing at $608000.0 for Q1 2026.
- Quarterly Interest & Investment Income fell 71.24% year-over-year to $608000.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $5.9 million (down 13.07% YoY) and the FY2025 annual result came in at $5.3 million, down 38.94% from the prior year.
- Interest & Investment Income was $608000.0 for Q1 2026 at UroGen Pharma, down from $5.3 million in the prior quarter.
- Across five years, Interest & Investment Income topped out at $5.3 million in Q4 2025 and bottomed at -$1.8 million in Q4 2023.
- A 5-year average of $776588.2 and a median of $128000.0 in 2022 frame the typical range for Interest & Investment Income.
- Peak annual rise in Interest & Investment Income reached 3200.0% in 2023, while the deepest fall reached 3895.83% in 2023.
- UroGen Pharma's Interest & Investment Income stood at $48000.0 in 2022, then tumbled by 3895.83% to -$1.8 million in 2023, then surged by 250.93% to $2.8 million in 2024, then soared by 93.75% to $5.3 million in 2025, then sank by 88.59% to $608000.0 in 2026.
- Business Quant data shows URGN's Interest & Investment Income at $608000.0 in Q1 2026, $5.3 million in Q4 2025, and $17000.0 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Int & Inv Inc (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 67,072.09 Bn | 67,072.09 Bn | - | - |
| 2 | Nanobiotix | 1,894.61 Bn | 1,894.55 Bn | - | - |
| 3 | Akari Therapeutics | 1,014.18 Bn | 1,014.18 Bn | - | - |
| 4 | BeOne Medicines | 471.64 Bn | 466.85 Bn | 1.35 Bn | 27.66 Mn |
| 5 | Vertex Pharmaceuticals | 121.72 Bn | 114.47 Bn | 2.59 Bn | 114.80 Mn |
| 6 | Regeneron Pharmaceuticals | 68.28 Bn | 59.52 Bn | 3.31 Bn | -65.80 Mn |
| 7 | Belite Bio | 61.40 Bn | 61.40 Bn | - | - |
| 8 | Argenx Se | 56.94 Bn | 56.94 Bn | 1.18 Bn | 44.00 Mn |
| 9 | Revolution Medicines | 37.37 Bn | 37.37 Bn | - | 19.51 Mn |
| 10 | UroGen Pharma | 2.05 Bn | 1.91 Bn | 46.82 Mn | 608,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 608,000.00 |
| Dec 31, 2025 | 5.33 Mn |
| Sep 30, 2025 | 17,000.00 |
| Jun 30, 2025 | -8,000.00 |
| Mar 31, 2025 | 2.11 Mn |
| Dec 31, 2024 | 2.75 Mn |
| Sep 30, 2024 | 267,000.00 |
| Jun 30, 2024 | 1.71 Mn |
| Mar 31, 2024 | 1.62 Mn |
| Dec 31, 2023 | -1.82 Mn |
| Sep 30, 2023 | 20,000.00 |
| Jun 30, 2023 | -109,000.00 |
| Mar 31, 2023 | 62,000.00 |
| Dec 31, 2022 | 48,000.00 |
| Sep 30, 2022 | 478,000.00 |
| Jun 30, 2022 | 128,000.00 |
| Mar 31, 2022 | -2,000.00 |
| Dec 31, 2021 | 96,000.00 |
| Sep 30, 2021 | -41,000.00 |
| Jun 30, 2021 | -98,000.00 |